Toyota|$18.22 (¥2,914)+2.44%▲ (in JPY terms)
Sony|$22.76 (¥3,639)-0.82%▼ (in JPY terms)
SoftBank|$52.33 (¥8,366)-3.08%▼ (in JPY terms)
MUFG|$19.56 (¥3,128)+2.69%▲ (in JPY terms)
Keyence|$504.87 (¥80,720)+3.04%▲ (in JPY terms)
Nintendo|$46.63 (¥7,455)+0.39%▲ (in JPY terms)
NTT|$0.93 (¥148)+0.00%▲ (in JPY terms)
Takeda|$29.66 (¥4,742)-2.23%▼ (in JPY terms)
Tokyo Electron|$379.15 (¥60,620)+12.87%▲ (in JPY terms)
Recruit|$67.64 (¥10,815)-0.28%▼ (in JPY terms)
ITOCHU|$11.59 (¥1,854)-0.22%▼ (in JPY terms)
Honda|$9.42 (¥1,506)+8.54%▲ (in JPY terms)
Shin-Etsu|$48.50 (¥7,754)+3.76%▲ (in JPY terms)
Tokio Marine|$44.32 (¥7,086)+0.57%▲ (in JPY terms)
Fast Retailing|$496.55 (¥79,390)-0.36%▼ (in JPY terms)
Toyota|$18.22 (¥2,914)+2.44%▲ (in JPY terms)
Sony|$22.76 (¥3,639)-0.82%▼ (in JPY terms)
SoftBank|$52.33 (¥8,366)-3.08%▼ (in JPY terms)
MUFG|$19.56 (¥3,128)+2.69%▲ (in JPY terms)
Keyence|$504.87 (¥80,720)+3.04%▲ (in JPY terms)
Nintendo|$46.63 (¥7,455)+0.39%▲ (in JPY terms)
NTT|$0.93 (¥148)+0.00%▲ (in JPY terms)
Takeda|$29.66 (¥4,742)-2.23%▼ (in JPY terms)
Tokyo Electron|$379.15 (¥60,620)+12.87%▲ (in JPY terms)
Recruit|$67.64 (¥10,815)-0.28%▼ (in JPY terms)
ITOCHU|$11.59 (¥1,854)-0.22%▼ (in JPY terms)
Honda|$9.42 (¥1,506)+8.54%▲ (in JPY terms)
Shin-Etsu|$48.50 (¥7,754)+3.76%▲ (in JPY terms)
Tokio Marine|$44.32 (¥7,086)+0.57%▲ (in JPY terms)
Fast Retailing|$496.55 (¥79,390)-0.36%▼ (in JPY terms)

JP3942400007

2026-03-23 Astellas Pharma Inc. “The EMA has received an application for approval of an additional indication for the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for muscle-invasive bladder cancer already treated with cisplatin.”

by

2026-03-23 Astellas Pharma Inc. “The EMA has received an application for approval of an additional indic … 続きを読む

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”

by

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む

Contact